Dianomi Therapeutics Inc., a biopharmaceutical company focused on osteoarthritis and pain with technology licensed from the Wisconsin Alumni Research Foundation (WARF), has established a partnership with and received an investment of $3 million from Ligand Pharmaceuticals. The partnership focuses on Dianomi’s proprietary Mineral Coated Microparticle (MCM) technology, developed at the University of Wisconsin-Madison, that is uniquely designed to provide stability and controlled release delivery of biologics and small molecule drugs.

Dianomi’s worldwide, exclusive license from WARF includes core intellectual property developed by William Murphy, Ph.D., a Dianomi co-founder and UW-Madison Professor of Biomedical Engineering and Orthopedics & Rehabilitation. Murphy’s BioInspired Materials Laboratory developed the MCM technology to harness the natural property of mineralized tissues (e.g. bones, teeth) to extend the therapeutic life of biological drugs. The MCM technology is designed to provide sustained release delivery, which can ultimately lower dosing and enhance patient compliance, thus impacting drug safety and efficacy.

“Traditional approaches for encapsulation and delivery of drugs utilize artificial polymers that often disrupt drug structure and function,” said Murphy, Chief Scientific Officer of Dianomi. “Our MCM technology overcomes this limitation by providing a matrix that naturally stabilizes the drug, with properties that can be tailored to the drug and its intended application. I am excited to advance this technology toward clinical applications that could benefit patients.” Read the full story here.